Clinical trial NCT03371979: Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Official title: A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Small-cell Lung Cancer
Lead sponsor: Aeglea Biotherapeutics
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2017-12-13
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.


Eligibility criteria: Key Inclusion Criteria:

1. Patient is able and willing to provide written informed consent
2. Be \> 18 years of age on day of signing informed consent
3. Have histologically or cytologically confirmed SCLC that meets:

   1. Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system
   2. Have not tolerated or have progressed or relapsed on or within 6 months of platinum-based chemotherapy
4. Have a performance status of ≤ 1 on the ECOG Performance Scale
5. Have measurable disease based on RECIST 1.1
6. Willing to undergo core needle or incisional biopsy to obtain fresh tumor tissue specimens
7. Demonstrate adequate organ function as evidenced by laboratory testing with specimens collected within 10 days prior to day 1 of cycle 1
8. Female child-bearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication
9. Sexually active male or female must be surgically sterile post-menopausal, or must agree to use a physician-approved method of birth control during the study through a minimum of 120 days after the last study drug administration.

Key Exclusion Criteria:

1. Has received more than 2 platinum-based regimens against SCLC
2. Has received pembrolizumab, or prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as part of any previous therapy, including trials
3. Has participated in Merck MK-3475 (pembrolizumab) clinical trials
4. Has received pegzilarginase as part of any previous therapy
5. Is currently participating in a study of an investigational agent or received the last dose of an investigational agent within 4 weeks prior to the first dose of treatment in this study (a shorter interval for kinase inhibitors or other short half-life drugs could be considered after approval from the Sponsor). Is currently participating in a study of an investigational device within 4 weeks of the first dose of treatment
6. Has a diagnosis of an immunodeficiency, is receiving systemic steroid therapy (except for physiological dose levels), or immunosuppressive therapies
7. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer) that has undergone potentially curative therapy
8. Has known central nervous system (CNS) metastases. However, patients with previously treated brain metastases may participate provided neurologic symptoms have stabilized, there is no evidence of new brain metastases or hemorrhage and they are not using steroids for brain metastases or for complications derived from their treatment for at least 7 days prior to the first dose of trial treatment
9. Has known carcinomatous meningitis
10. Has an active autoimmune disease requiring systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy are an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment
11. Has evidence of interstitial lung disease, history of non-infectious pneumonitis that required steroids, or current pneumonitis
12. Inadequately controlled hypertension (defined as systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 120 mmHg) on more than one occasion in the month before planned day of infusion
13. Currently taking 3 or more anti-hypertensive medications
14. Prior history of hypertensive crisis or hypertensive encephalopathy
15. History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac or vascular surgery within 6 months prior to day 1 of study treatment
16. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
17. Has a known history of Human Immunodeficiency Virus (HIV) (positive for HIV p24 antigen or HIV 1/2 antibodies)
18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected)
19. Has a known history of active tuberculosis (Bacillus tuberculosis)
20. Has had an allogenic tissue/solid organ transplant.

Primary outcomes:
measure: 1. Phase 1: Incidence of treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: Estimated up to 6 months
measure: Phase 2: Efficacy determined by Objective Response Rate (ORR:CR+PR) per RECIST 1.1.
timeFrame: Estimated up to 6 months
Secondary outcomes:
measure: Objective Response Rate
timeFrame: At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
measure: Clinical Benefit Rate
timeFrame: At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
measure: Time to Response
timeFrame: At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
measure: Duration of Response
timeFrame: At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months
measure: Progression free survival
timeFrame: From first treatment up to 24 months
measure: Overall Survival
timeFrame: From first treatment up to 24 months
measure: Phase 2: Incidence of treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: From first treatment up to 24 months
Other outcomes:
Locations:
city: Mobile
country: United States
facility: University of Alabama, Mitchell Cancer Institute
state: Alabama
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Denver
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Orange City
country: United States
facility: Mid Florida Hematology and Oncology Centers
state: Florida
city: Pensacola
country: United States
facility: Woodlands Medical Specialists, PA
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Saint Louis
country: United States
facility: Washington University
state: Missouri
city: Omaha
country: United States
facility: Nebraska Cancer Specialists
state: Nebraska
city: Paramus
country: United States
facility: The Valley Hospital, Luckow Pavilion
state: New Jersey
city: Cincinnati
country: United States
facility: Oncology Hematology Care Inc.
state: Ohio
city: Portland
country: United States
facility: Providence Cancer Center
state: Oregon
city: Pittsburgh
country: United States
facility: UPMC Cancer Center
state: Pennsylvania
city: Charleston
country: United States
facility: Charleston Hematology Oncology Associates
state: South Carolina
city: Germantown
country: United States
facility: West Clinic
state: Tennessee
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Houston
country: United States
facility: Texas Oncology-Memorial City
state: Texas
city: Tyler
country: United States
facility: Texas Oncology-Tyler
state: Texas
city: Blacksburg
country: United States
facility: Oncology & Hematology Associates of SW Virginia
state: Virginia
city: San Juan
country: Puerto Rico
facility: Fundacion De Investigacion, Hematology/Oncology
Study officials:
affiliation: Aeglea Biotherapeutics, Inc.
name: Josie Gayton
role: STUDY_DIRECTOR
References: